Functional characterization of in vivo effector CD4+ and CD8+ T cell responses in acute Toxoplasmosis: An interplay of IFN-γ and cytolytic T cells

Jongert, Erik; Lemière, Arnaud; Ginderachter, Jo A. Van; Craeye, Stéphane De; Huygen, Kris; D’Souza, Sushila

doi:10.1016/j.vaccine.2010.01.031

Cited by 42 publications

(45 citation statements)

References 60 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It was suggested that treatment of the parasitic lesions with hydroalcoholic extract of T. vulgaris stimulates natural killer cells activity and releases nitric acid and tumor necrosis factor (TNF-α) from macrophages [26]. TNF-α plays a crucial role in controlling the infection caused by T. gondii because it can activate CD8+ T cytotoxic cells to transform into major cytotoxic effector cells for destroying tachyzoite-infected cells, restricting parasite dissemination throughout acute infection and inhibiting cyst formation throughout chronic infection [27,28].…”

Section: Tablementioning

confidence: 99%

Hepatoprotective activity of Thymus vulgaris extract against Toxoplasma gondii infection

El-Sayed¹

2017

APJTD

View full text Add to dashboard Cite

Section: Tablementioning

confidence: 99%

Hepatoprotective activity of Thymus vulgaris extract against Toxoplasma gondii infection

El-Sayed¹

2017

APJTD

View full text Add to dashboard Cite

“…As T. gondii is an obligate intracellular parasite, protective immunity to T. gondii is largely mediated by Th1 cell-mediated immunity [6,7]. Previous studies have shown that induction of both lymphocyte proliferation and IFN-γ production (one of Th1-type cytokines) positively correlates with protective Th1 cell-mediated immunity against T. gondii [43,44,51].…”

Section: Protective Immunity By Toxoplasma Sag-loaded Microparticlesmentioning

confidence: 99%

“…Our previous studies [22][23][24] and those recorded by others [32][33][34] have shown that facilitation of uptake and delivery of PLG-rSAG microparticles by macrophages can lead to more effective antigen processing and presentation to T lymphocytes capable of inducting cell-mediated immunity. Thus, the high survival rates in mice have demonstrated that PLG-rSAG microparticles effectively elicit protective Th1 cell-mediated immunity to remove tachyzoite-infected cells for limiting parasite dissemination during the experimental tachyzoite challenge [7].…”

Section: Protective Immunity By Toxoplasma Sag-loaded Microparticlesmentioning

confidence: 99%

“…Numerous earlier studies have demonstrated that cell-mediated immunity is considered as the 'appropriate' immune response in the prevention of T. gondii infection [7]. Therefore, potent adjuvants that can improve cell-mediated immunity have to include in Toxoplasma vaccine development in the future.…”

Section: Introductionmentioning

confidence: 99%

“…Therefore, potent adjuvants that can improve cell-mediated immunity have to include in Toxoplasma vaccine development in the future. In addition, gamma interferon (IFN-γ), one of Th1-type cytokines, mainly produced by CD4 + Th1 cells is able to subsequently stimulate CD8 + Tc cells to convert into cytotoxic effector cells for preventing acute and chronic T. gondii infection [6][7][8]. Thus, effective protection against T. gondii infection is critically dependent on the IFN-γ-associated Th1 cell-mediated immunity.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Microparticle Vaccines Against Toxoplasma gondii

Yang¹

2017

Toxoplasmosis

View full text Add to dashboard Cite

Significant information indicates that future investigations on Toxoplasma vaccine development have to include adjuvants for enhancing protective immunity against Toxoplasma gondii. Especially, safe and effective adjuvants capable of fulfilling Th1-dependent cellmediated immunity appear to be more likely to be allowed to use for anti Toxoplasma vaccine development. Recently, biodegradable and biocompatible polymers, such as poly (lactide-co-glycolide) (PLG) polymers, have been utilized as safe and efficacious adjuvants to encapsulate antigens for producing long-term release microparticle-based vaccines. PLG microencapsulation allows the sustained release of antigens and facilitates antigen uptake via antigen-presenting cells (APCs) to favorably generate Th1 cell-mediated immunity, which is required for the prevention of T. gondii infection. In our recent work, recombinant surface antigens (rSAGs), including rSAG1, rSAG2, and rSAG1/2, have been, respectively, encapsulated with the PLG polymer for production of PLG-encapsulated rSAG1 (PLG-rSAG1), PLG-encapsulated rSAG2 (PLG-rSAG2), or PLG-encapsulated rSAG1/2 (PLG-rSAG1/2) microparticles. This chapter describes adjuvant effect of PLG microparticles, controlled release of PLG microparticles, PLG microparticles-immune system interaction, Toxoplasma SAG-loaded PLG microparticles, protective immunity by Toxoplasma SAG-loaded PLG microparticles, and future prospects. PLG microparticle vaccines would be advantageous for their application in the development of long-lasting vaccines against T. gondii for future use in humans and animals.

show abstract

Enhancement of the protective efficacy of a ROP18 vaccine against chronic toxoplasmosis by nasal route

Rashid¹,

Moiré²,

Héraut³

et al. 2016

Med Microbiol Immunol

View full text Add to dashboard Cite

Infection with the parasite Toxoplasma gondii causes serious public health problems and is of great economic importance worldwide. No vaccine is currently available, so the design of efficient vaccine strategies is still a topical question. In this study, we evaluated the immunoprophylactic potential of a T. gondii virulence factor, the rhoptry kinase ROP18, in a mouse model of chronic toxoplasmosis: first using a recombinant protein produced in Schneider insect cells adjuvanted with poly I:C emulsified in Montanide SV71 by a parenteral route or adjuvanted with cholera toxin by the nasal route and second using a DNA plasmid encoding ROP18 adjuvanted with GM-CSF ± IL-12 DNA. If both intranasal and subcutaneous recombinant ROP18 immunizations induced predominantly anti-ROP18 IgG1 antibodies and generated a mixed systemic Th1-/Th2-type cellular immune response characterized by the production of IFN-γ, IL-2, Il-10 and IL-5, only intranasal vaccination induced a mucosal (IgA) humoral response in intestinal washes associated with a significant brain cyst reduction (50 %) after oral challenge with T. gondii cysts. DNA immunization induced antibodies and redirected the cellular immune response toward a Th1-type response (production of IFN-γ and IL-2) but did not confer protection. These results suggest that ROP18 could be a component of a subunit vaccine against toxoplasmosis and that strategies designed to enhance mucosal protective immune responses could lead to more encouraging results.

show abstract

Functional characterization of in vivo effector CD4+ and CD8+ T cell responses in acute Toxoplasmosis: An interplay of IFN-γ and cytolytic T cells

Cited by 42 publications

References 60 publications

Hepatoprotective activity of Thymus vulgaris extract against Toxoplasma gondii infection

Hepatoprotective activity of Thymus vulgaris extract against Toxoplasma gondii infection

Microparticle Vaccines Against Toxoplasma gondii

Enhancement of the protective efficacy of a ROP18 vaccine against chronic toxoplasmosis by nasal route

Contact Info

Product

Resources

About